Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.69 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.69 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.69 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.69 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.69 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.69 |
| ▸ | PLAU | P00749 | 1/20 | 0.60 |
| ▸ | HTR6 | P50406 | 1/20 | 0.56 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.56 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.56 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.56 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.56 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.56 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6190834 | 0.86 | HDAC8 (0.62) | HDAC8HDAC6HDAC1HDAC2HDAC10 | |
| SCHEMBL12850690 | 0.86 | HDAC8 (0.65) | HDAC8HDAC6HDAC1HDAC2HDAC10 | |
| SCHEMBL6085688 | 0.85 | HDAC1 (0.54) | HDAC8HDAC6HDAC1HDAC2HDAC10 | |
| SCHEMBL12472242 | 0.84 | HDAC8 (0.70) | HDAC8HDAC6HDAC1HDAC2HDAC10 | |
| SCHEMBL3109875 | 0.84 | HDAC6 (0.61) | HDAC8HDAC6HDAC1HDAC2HDAC10 | |
| SCHEMBL8685995 | 0.84 | HDAC8 (0.60) | HDAC8HDAC6HDAC1HDAC2HDAC10 | |
| SCHEMBL15705726 | 0.83 | HDAC8 (0.78) | HDAC8HDAC6HDAC1HDAC2HDAC10 | |
| SCHEMBL6087475 | 0.83 | HDAC8 (0.61) | HDAC8HDAC6HDAC1HDAC2HDAC10 | |
| SCHEMBL1749348 | 0.82 | HDAC1 (0.72) | HDAC8HDAC6HDAC1HDAC2HDAC10 | |
| SCHEMBL6086717 | 0.82 | HDAC8 (0.58) | HDAC8HDAC6HDAC1HDAC2HDAC10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2670733-B1 | N-HYDROXYBENZAMIDE DERIVATIVES AS HDAC INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | UNIV ILLINOIS (US) | 2019-04-10 | — | — | EP | disclosed |
| EP-2670733-B1 | N-HYDROXYBENZAMIDE DERIVATIVES AS HDAC INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | UNIV ILLINOIS (US) | 2019-04-10 | — | — | EP | disclosed |
| US-RE47009-E1 | HDAC inhibitors and therapeutic methods using the same | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2018-08-28 | — | — | US | disclosed |
| US-9650379-B2 | Azaindole derivatives as selective histone deacetylase (HDAC) inhibitors and pharmaceutical compositions comprising the same | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2017-05-16 | — | — | US | disclosed |
| US-20160289230-A1 | NOVEL AZAINDOLE DERIVATIVES AS SELECTIVE HISTONE DEACETYLASE (HDAC) INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2016-10-06 | — | — | US | disclosed |
| US-9249087-B2 | HDAC inhibitors and therapeutic methods using the same | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2016-02-02 | — | — | US | disclosed |
| US-20140128408-A1 | HDAC INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2014-05-08 | — | — | US | disclosed |
| US-20140128408-A1 | HDAC INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2014-05-08 | — | — | US | disclosed |
| US-20140128408-A1 | HDAC INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2014-05-08 | — | — | US | disclosed |
| EP-2670733-A2 | HDAC INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | The Board of Trustees of the University of Illinois (US) | 2013-12-11 | — | — | EP | disclosed |
| EP-1322646-A1 | 2-(1H-INDOL-3-YL)-2-OXO-ACETIC ACID AMIDES WITH ANTITUMOR ACTIVITY | Novuspharma S.p.A. (IT) | 2003-07-02 | — | — | EP | disclosed |
| CN-1413205-A | 2- (1H-indol-3-yl) -2-oxo-acetamides with antitumor activity | NOVUSPHARMA SPA (IT) | 2003-04-23 | — | — | CN | disclosed |
| EP-1244652-A1 | 2-(1H-INDOL-3-YL)-2-OXO-ACETAMIDES WITH ANTITUMOR ACTIVITY | Cell Therapeutics Europe S.R.L. (IT) | 2002-10-02 | — | — | EP | disclosed |
| EP-1242432-A1 | PHOSPHONIC ACID DERIVATIVES AS INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE 1B (PTP-1B) | MERCK FROSST CANADA INC. (CA) | 2002-09-25 | — | — | EP | disclosed |
| WO-2002008225-A1 | 2-(1H-INDOL-3-YL)-2-OXO-ACETIC ACID AMIDES WITH ANTITUMOR ACTIVITY | NOVUSPHARMA S.P.A. (IT) | 2002-01-31 | — | — | WO | disclosed |
| WO-2001047916-A1 | 2-(1H-INDOL-3-YL)-2-OXO-ACETAMIDES WITH ANTITUMOR ACTIVITY | NOVUSPHARMA S.P.A. (IT) | 2001-07-05 | — | — | WO | disclosed |
| WO-2001046205-A1 | PHOSPHONIC ACID DERIVATIVES AS INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE 1B (PTP-1B) | MERCK FROSST CANADA & CO. (CA) | 2001-06-28 | — | — | WO | disclosed |
| US-5877199-A | ALZHEIMER'S DISEASE; SEDATIVE | SANKYO COMPANY, LIMITED (JP) | 1999-03-02 | — | — | US | disclosed |
| EP-0804416-A1 | HETEROCYCLIC COMPOUNDS, USEFUL AS ALLOSTERIC EFFECTORS AT MUSCARINIC RECEPTORS | SANKYO COMPANY LIMITED (JP) | 1997-11-05 | — | — | EP | disclosed |
| WO-1996003377-A1 | HETEROCYCLIC COMPOUNDS, USEFUL AS ALLOSTERIC EFFECTORS AT MUSCARINIC RECEPTORS | SANKYO COMPANY, LIMITED (JP) | 1996-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140128408-A1 | HDAC INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | HDAC1, HDAC9, HDAC8 | HDAC8 3/4885HDAC6 9/4885HDAC1 1/4885 |
| US-20160289230-A1 | NOVEL AZAINDOLE DERIVATIVES AS SELECTIVE HISTONE DEACETYLASE (HDAC) INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | HDAC5, HDAC1, HDAC2 | HDAC8 10/4885HDAC6 4/4885HDAC1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.